Cargando…

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease

(1) Background: GP2017 is one of the biosimilar drugs of adalimumab, one of the anti-TNF agents used for inflammatory bowel disease (IBD). To date, there is little real-world data about the use of GP2017 in IBD patients. The aim of our study was to evaluate the effectiveness and safety of this biosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vernero, Marta, Bezzio, Cristina, Ribaldone, Davide G., Costa, Stefania, Scalvini, Davide, Tribocco, Elisa, Manes, Gianpiero, Saibeni, Simone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647534/ https://www.ncbi.nlm.nih.gov/pubmed/37959304 http://dx.doi.org/10.3390/jcm12216839

Ejemplares similares

Insights into the role of gastrointestinal ultrasound in ulcerative colitis
por: Bezzio, Cristina, et al.
Publicado: (2021)

Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis
por: Bezzio, Cristina, et al.
Publicado: (2023)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations
por: Bezzio, Cristina, et al.
Publicado: (2022)

Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
por: Mocci, Giammarco, et al.
Publicado: (2022)

Planning phase two for endoscopic units in Northern Italy after the COVID-19 lockdown: An exit strategy with a lot of critical issues and a few opportunities
por: Manes, Gianpiero, et al.
Publicado: (2020)

Severe Inflammatory Bowel Disease Flares and COVID-19: Expand the Gastroenterology–Surgery Team to Include an Infectious Disease Specialist
por: Bezzio, Cristina, et al.
Publicado: (2021)

Tolerability of Bowel Preparation and Colonoscopy in IBD Patients: Results From a Prospective, Single-Center, Case–Control Study
por: Bezzio, Cristina, et al.
Publicado: (2020)

NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease
por: Colombo, Giorgia, et al.
Publicado: (2023)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Efficacy of withdrawal time monitoring in adenoma detection with or without the aid of a full-spectrum scope
por: Manes, Gianpiero, et al.
Publicado: (2019)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)

Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
por: Wang, Fang, et al.
Publicado: (2023)

Inflammatory Bowel Disease Nurse—Practical Messages
por: Rosso, Chiara, et al.
Publicado: (2021)

Epidemiology of Inflammatory Bowel Diseases: A Population Study in a Healthcare District of North-West Italy
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

Artificial intelligence in gastrointestinal endoscopy for inflammatory bowel disease: a systematic review and new horizons
por: Tontini, Gian Eugenio, et al.
Publicado: (2021)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY
por: Cingolani, A., et al.
Publicado: (2022)

SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves
por: Bezzio, Cristina, et al.
Publicado: (2023)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
por: Petric, Zvonimir, et al.
Publicado: (2022)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar
por: Lee, JongAh Joanne, et al.
Publicado: (2023)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study
por: Barberio, Brigida, et al.
Publicado: (2021)

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
por: Velayudhan, Jyoti, et al.
Publicado: (2016)

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts
por: Derikx, Lauranne A A P, et al.
Publicado: (2021)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Adalimumab biosimilar in a pediatric patient: Clinical and in vivo reflectance confocal microscopy evaluation
por: Megna, Matteo, et al.
Publicado: (2022)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
por: Midha, Vandana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_naron8sk6qruq4mpmiansaa5k0